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GentamicinCcomplex is amixtureof aminoglycoside
antibiotics used to treat severeGram-negativebacte-
rial infections.We report here key features of the late-
stage biosynthesis of gentamicins. We show that the
intermediate gentamicin X2, a known substrate for
C-methylation at C-60 to form G418 catalyzed by the
radical SAM-dependent enzyme GenK, may instead
undergo oxidation at C-60 to form an aldehyde, cata-
lyzed by the flavin-linked dehydrogenase GenQ. Sur-
prisingly, GenQacts in both branches of the pathway,
likewise oxidizing G418 to an analogous ketone.
Amination of these intermediates, catalyzed mainly
by aminotransferase GenB1, produces the known
intermediates JI-20A and JI-20B, respectively. Other
pyridoxal phosphate-dependent enzymes (GenB3
and GenB4) act in enigmatic dehydroxylation steps
that convert JI-20A and JI-20B into the gentamicin
C complex or (GenB2) catalyze the epimerization of
gentamicin C2a into gentamicin C2.
INTRODUCTION
Gentamicins are clinically valuable aminoglycoside antibiotics
containing modified sugar units, including an unusual aminocy-
clitol ring (2-deoxystreptamine [2-DOS]; Houghton et al., 2010;
Park et al., 2013). Gentamicins inhibit protein synthesis by inter-
fering with initiation, codon fidelity, and translocation. They
are isolated from the filamentous bacterium Micromonospora
echinospora as gentamicin C complex, a mixture of five compo-
nents (Figure 1). Gentamicin C complex is a mainstay of the
treatment of life-threatening sepsis caused by Gram-negative
bacterial infections. It also shows promise as a lead for treatment
of inherited diseases associated with premature stop codons
(Hainrichson et al., 2008; Linde and Kerem, 2008) and acts as
a sensitizing agent for NCI-H460 lung cancer cells, increasing
the efficacy of various anticancer agents (Cuccarese et al.,
2013). Unfortunately, these vital drugs entail a serious risk of kid-
ney damage and hearing loss (Bockenhauer et al., 2009). Most608 Chemistry & Biology 21, 608–618, May 22, 2014 ª2014 The Authstudies on the mechanisms of gentamicin toxicity have used
the commercial mixture, despite evidence that an individual
component of the gentamicin mixture may have lower toxicity
(Sandoval et al., 2006; Kobayashi et al., 2008). As a prerequisite
for engineering to favor the production of a particular gentamicin,
we have undertaken a detailed investigation of the late steps in
the pathway.
The outlines of the gentamicin pathway were established by
isolating blocked mutants after random mutagenesis and moni-
toring the fate of compounds fed to such blocked strains (Testa
and Tilley, 1975, 1976; Kase et al., 1982a, 1982b). It was shown
that thepathwaybranchesatgentamicinX2 (Figure1) and thefinal
steps involve a series of oxidations, transaminations, and C- and
N-methylations, as well as the intriguing loss of two hydroxyl
groups from one of the sugar rings. Many biosynthetic gene
clusters that govern aminoglycoside biosynthesis have been
sequenced (Ota et al., 2000; Unwin et al., 2004; Kharel et al.,
2004a, 2004b, 2004c; Huang et al., 2005; Subba et al., 2005;
Aboshanab, 2005; Hong et al., 2009). As a result, rapid progress
has been made in identifying the common enzymatic steps that
lead to the 2-DOS scaffold, and thence to the pseudodisacchar-
ide paromamine (Figure 1; Llewellyn and Spencer, 2006; Thibo-
deaux et al., 2008; Kudo and Eguchi, 2009; Kudo et al., 2009).
The intermediate pseudotrisaccharide gentamicin A2 (Figure 1)
has beenproducedby heterologous expression of a subset of the
gentamicin biosynthetic genes in the host strain Streptomyces
venezuelae (Park et al., 2008). This has enabled a sharper focus
on those genes likely to govern the later steps of gentamicin
biosynthesis. Specific late gene knockouts have been made in
genD1 and genK, both of which are predicted based on bio-
informatic analysis (Figure S1A available online) to encode class
B radical S-adenosylmethionine-dependent C-methyltrans-
ferases (Zhang et al., 2012). The replacement of genD1, also
known as gntE (Unwin et al., 2004) or gtmI (Kharel et al., 2004c),
by a thiostrepton resistance gene (tsr) led to accumulation of
gentamicin A2 (Figure 1; Kim et al., 2008). These authors inter-
preted their result as meaning that GenD1 catalyzes N-methyl-
ationat the30 0-NH2 rather thanC-methylationatC-40 0 of thexylose
ring of gentamicin A2; but this, and the exact order of events, re-
mains to be established. Disruption of genK, also known as gntK
(Unwin et al., 2004) or gacD (Kharel et al., 2004c), has been shown
to result in preferential accumulation of gentamicin C1a (Karkiors
Figure 1. Proposed Biosynthetic Pathway
from Paromamine to the Gentamicin C
Complex
The early steps in the pathway lead from the
pseudodisaccharide paromamine to the branch
point at gentamicin X2. The five main components
of the clinically-used gentamicin C complex are
shown in green. The proposed roles of the
radical S-adenosylmethionine-dependent methyl-
transferases GenD1 and GenK are indicated. The
role of GenK has been established by previous
in vitro work. Intermediates 60-DOX and 60-DOG,
newly-detected in this study, are shown inblue. The
roles of dehydrogenase GenQ and aminotrans-
ferase GenB1 are revealed in this study, as well as
the involvement of GenB3 and GenB4 in the steps
from intermediates JI-20A and JI-20B to the
gentamicin C complex, and of GenB2 in epimeri-
zation of gentamicin C2a to gentamicin C2.
For further details see the text. KMBA, 2-keto-
3-methylthiobutyric acid; 60-DOG, 60-dehydro-
60-oxo-G418; 60-DOX, 60-dehydro-60-oxo-genta-
micin X2.
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been demonstrated to catalyze C-methylation in vitro of C-60 in
gentamicin X2 to form G418 (Kim et al., 2013).
By analysis of the gentamicin-related metabolites accumu-
lated in strains bearing single and multiple specific gene dele-
tions, by following the bioconversion of specific intermediatesChemistry & Biology 21, 608–6fed to such mutants, and by assaying in-
dividual steps using purified recombinant
enzymes, we demonstrate that control at
the branch point is shared between GenK
and the flavin-linked dehydrogenase
GenQ. Importantly, GenQ operates in
both branches of the pathway, and is
essential for the oxidation of both X2
and G418 (Figure 1). We have also ob-
tained fresh insights into the respective
catalytic contributions of four pyridoxal
phosphate-dependent enzymes GenB1,
GenB2, GenB3, and GenB4.
RESULTS
GenK Acts at the X2 Branch Point
and Is Essential for the Production
of G418 and Gentamicins C2a, C2,
and C1
To confirm the previously established role
of genK at the gentamicin X2 branch
point, this gene was knocked out by tar-
geted in-frame deletion (Figure S2(1)A).
The mutant was confirmed by PCR and
Southern hybridization (Figures S2(1)B
and S2C). Liquid chromatography-elec-
trospray ionization high-resolution mass
spectrometry (LC-ESI-HRMS) analysis
confirmed that in this mutant, productionof G418, JI-20B, and gentamicins C1, C2, and C2a was abol-
ished (Figure 2C and Figure S3B). In contrast, levels of genta-
micin X2, JI-20A, and gentamicins C1a and C2b were all
substantially increased compared to wild-type (Figure 2C and
Figure S3B). Complementation of the DgenK mutant, carried
out by using plasmid pWHU67 containing genK under the control18, May 22, 2014 ª2014 The Authors 609
Figure 2. LC-ESI_HRMS Analysis of the Production of Gentamicin
C Complex and Gentamicin-Related Intermediates by Micromono-
spora echinospora
(A) gentamicin C standard mixture.
(B) Wild-type.
(C) DgenK mutant.
(D) DgenK::genK mutant.
(E) DgenK mutant fed with G418.
(F) DgenQ mutant.
(G) DgenQ::genQ mutant.
(H) DgenQ::neo11 mutant.
(I) DgenQDgenK mutant.
See also Figures S1–S3. For details of the LC-ESI-HRMS analysis, see the
Supplemental Information.
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610 Chemistry & Biology 21, 608–618, May 22, 2014 ª2014 The Authof the PermE* promoter (Figure S2(4)A), restored the production
of gentamicin C complex and of various intermediates to wild-
type levels (Figure 2D). Chemical complementation of the DgenK
mutant by feeding G418 also restored production of JI-20B,
gentamicin C2, C2a (the C-60 epimer of C2), and C1 (Figure 2E).
Dehydrogenase GenQ Is Essential in Both Branches of
the Gentamicin Pathway that Diverges from X2
The gene genQ (also known as gntX (Unwin et al., 2004) or gacJ
(Kharel et al., 2004c)) is predicted to encode a flavin-linked
dehydrogenase with significant sequence identity to enzymes
catalyzing similar steps in other aminoglycoside pathways (Fig-
ure S1B). GenQ was therefore an attractive candidate to act at
the X2 branch point and initiate the biosynthesis of C1a and
the minor component C2b (also known as sagamicin; Figure 1).
To investigate the role of genQ, a 1494 bp internal DNA fragment
was deleted in-frame (Figure S2(2)A). The mutant was confirmed
by PCR and Southern hybridization (Figures S2(2)B and S2C).
LC-ESI-HRMS analysis revealed that production was abolished
in the DgenQ mutant not only of JI-20A and the downstream
gentamicins C1a and C2b, but unexpectedly also of JI-20B
and gentamicins C2, C2a, and C1 (Figure 2F and Figure S3B).
Meanwhile, G418 was accumulated to levels 100-fold higher
than wild-type (Figure S3B). These data strongly suggest that
genQ is not only involved at the X2 branch point in the first
step toward C1a and C2b, but is also essential in the other
branch of the pathway for the oxidation of G418 that leads on
to JI-20B and finally to C2, C2a, and C1. The LC-ESI-HRMS
analysis did not detect 60-dehydro-60-oxo-G418 (60-DOG) or 60-
dehydro-60-oxo-gentamicin X2 (60-DOX; Figure 1), the presumed
products of GenQ-catalyzed oxidation.
The dual function of genQ was further supported by showing
that the DgenQ mutant could be homologously complemented
by introduction of pWHU163, in which genQ is under the
control of the constitutive promoter PermE* (Figure 2G and Fig-
ure S2(4)B). This mutant was also heterologously complemented
by introduction of pWHU165 (Figure 2H and Figure S2(4)C) con-
taining neo11, a gene from the neomycin biosynthetic pathway
that is homologous to genQ (Huang et al., 2007). LC-ESI-
HRMS analysis of fermentation extracts from the mutants
DgenQ::genQ and DgenQ::neo11 demonstrated that all compo-
nents of the gentamicin C complex were restored to wild-type
levels (Figures 2G and 2H). The DgenQDgenK mutant was also
generated by targeted in-frame deletions (Figure S2(3)), and
LC-ESI-HRMS analysis showed that, as expected, onlyors
Figure 3. Production of Gentamicin C Components and Related
Intermediates by M. echinospora genB Mutants
Data are shown for three genBmutants that continue to produce gentamicin C
components. Data for a further 12 genBmutants (Figure S4B) that were found
to produce no gentamicin C complex are shown in Table S1. The starred peak
is from an unknown metabolite with the same mass as gentamicin X2.
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than in the wild-type (Figure 2I and Figure S3B).
GenB1 Is the Chief Aminotransferase Partner for GenQ
while GenB3 and GenB4 Participate in Dehydroxylation
The gentamicin biosynthetic gene cluster in M. echinospora
contains four genes that appear to encode class III pyridoxal
phosphate-dependent transaminases (Figure S4A), any of which
might catalyze the transamination steps that lead in parallel to
JI-20A and JI-20B, respectively. The genB1 gene was deleted
in-frame, and the identity of the resulting mutant was confirmed
by PCR and Southern blot analysis (Figure S4B(1)). Similarly,
genB2, genB3, and genB4 were each individually disrupted
by in-frame deletion (Figures S4B(2) to S4B(4)). Starting from
these mutants, similar methods were used to generate all six
double mutants (Figure S4B(5) to S4B(10)), all four triple mu-
tants (Figures S4B(11) to S4B(14)), and the quadruple mutant
DgenB4DgenB1DgenB3DgenB2 (Figure S4B(15)). Each of these
mutant strains was fermented in liquidmedium, as detailed in the
Experimental Procedures section, and gentamicin C complex
and related metabolites were extracted, purified by ion ex-
change and submitted to LC-ESI-HRMS analysis (Figure 3 and
Table S1) for comparison with wild-type.ChemThis analysis revealed that in the quadruple mutant only X2
andG418were produced (the latter at levels about 18-fold higher
than in wild-type), a result that argues against any contribution
to transamination activity from enzymes other than these four.
In fact of the 15 mutants examined (Table S1), only DgenB1,
DgenB2, and the double mutant DgenB2DgenB1 produced
any gentamicin C complex components (Figure 3). Deletion of
genB1 substantially lowered, but did not abolish, the levels of
individual components of the gentamicin C complex. This argues
strongly that at least one other aminotransferase can partially
fulfill the role of GenB1. Nevertheless, these data are consistent
with GenB1 making the chief contribution to amination of
both 60-DOX and 60-DOG. In the DgenB2 mutant and in the
DgenB2DgenB1 double mutant, levels of gentamicins C1a and
C2b in the ‘‘left-hand’’ branch (Figure 1) were significantly
reduced. In the ‘‘right-hand’’ branch, production of C2a was
increased more than 7-fold, while C2 and C1 production was
completely blocked. Initially, we identified theC2apeak (Figure 3)
as C2b from the ‘‘left-hand’’ branch (these metabolites have
similar retention times, the same mass and the same MS-MS
fragmentation pattern). However, further analysis and spiking
with authentic C2a, C2, andC1 confirmed that C2a is the product
(Figure S5). This finding leads directly to a proposal for the role of
GenB2 in the pathway (see the Discussion section). All genB
mutants continued to produce the known late-stage biosynthetic
intermediates: gentamicin X2 at the branch point, G418 and
JI-20B on the ‘‘right-hand’’ branch, and JI-20A on the ‘‘left-
hand’’ branch of the pathway (Figure 1) at approximately wild-
type levels (Figure 3 and Table S1). Again, these results show
that other aminotransferases can substitute for GenB1.
Deletion of either genB3 or genB4, alone or in combination with
other genB genes, abolished the production of all five gentamicin
Ccompounds (TableS1). For theDgenB3mutant,bothJI-20Aand
JI-20B were present at higher (more than 10-fold) levels than in
wild-type, consistent with the likely involvement of GenB3 in the
enigmatic dehydroxylation steps of gentamicin biosynthesis,
rather than in amination of X2 and G418. In the DgenB4 mutant,
too,andalso in thedoublemutantDgenB4DgenB3, theCcomplex
was completely lacking whereas intermediates X2, G418, JI-20A,
and JI-20Bwere still present at eitherwild-typeor slightly elevated
levels. This demonstrated that GenB4 also has an essential role in
dehydroxylation, and that this role is distinct from that of GenB3.
Other double mutants showed different levels of intermediates
X2, G418, JI-20A, and JI-20B that reflect the differing contribution
of each GenB enzyme to transamination. When the triple mutants
were examined, in which only one of the four genB genes remains
functional, DgenB2DgenB4DgenB3 was found to accumulate
wild-type levels of JI-20Aandhigh levels ofG418andJI-20B, con-
firming that the presence of GenB1 alone suffices for the reaction
of both X2 andG418. The other triplemutants all showed very low
levels of both JI-20A and JI-20B compared to wild-type, again
indicating a minor role for GenB2, GenB3, or GenB4 in catalyzing
either transamination.
Recombinant GenQ Catalyzes 60-Oxidation of G418 and
Gentamicin X2
Recombinant GenQ was expressed in Escherichia coli to assay
its ability to catalyze the 60-dehydrogenation of both gentamicin
X2 and G418. GenQ as published is shorter (40 amino acidistry & Biology 21, 608–618, May 22, 2014 ª2014 The Authors 611
Figure 4. LC-MS Analysis of GenQ/GenB1-Catalyzed Dehydrogenation and Transamination of G418
Selective ion monitoring was carried out on (A) [M+H]+ (m/z 497) and [M+Na]+ (m/z 519) ions of G418; (B) the [M+Na]+ (m/z 517) ion of 60-DOG, the product of
GenQ-catalyzed 60-dehydrogenation of G418; (C) [M+H]+ (m/z 496) and [M+Na]+ (m/z 518) ions of JI-20B, the product of GenB1 catalyzed 60-amination of 60-DOG
using L-methionine as an amino donor. MS/MS analysis of [M+H]+ (m/z 497), [M+Na]+ (m/z 517), and [M+H]+ (m/z 496) ions is also shown. The peak atm/z 318.1 in
Figure 4B arises by further loss of water from fragment m/z 335.93. See also Figures S6 and S7.
Chemistry & Biology
Gentamicin Biosynthesisresidues) at the N terminus than close homologs in other amino-
glycoside biosynthetic pathways (Figure S1B). We therefore
amplified two longer versions of genQ: One, designated
LM_genQ, starts from the rare start codon CTG (Missiakas
et al., 1993) and provides an extra 19 N-terminal residues,
whereas the second version, VM_genQ, provides an extra 38
N-terminal residues absent in the original GenQ protein (Fig-
ure S6A). N-His6-tagged VM_GenQ was expressed as a soluble
protein in E. coli (Figure S6B). Purified VM_GenQ had a yellow
color and major absorption peaks at 370 nm and 445 nm (Fig-
ure S6C), indicating the presence of a flavin prosthetic group.
A solution of VM_GenQ was deproteinized and flavin adenine612 Chemistry & Biology 21, 608–618, May 22, 2014 ª2014 The Authdinucleotide (FAD) (m/z 786 [M+H]+ and m/z 808 [M+Na]+) was
detected in the supernatant with LC-ESI-MS analysis. LM_GenQ
did not contain bound flavin, so was not studied further.
VM_GenQ (hereafter referred to asGenQ) was tested for dehy-
drogenase activity using G418 and gentamicin X2 as substrates,
as described in the Experimental Procedures. LC-ESI-MS anal-
ysis of the reaction mixture containing GenQ and G418 revealed
a new peak eluting at a slightly earlier retention time, with m/z =
495 [M+H]+ and m/z = 517 [M+Na]+; Figure 4B), two mass units
less than G418 (Figure 4A), as expected for the conversion
of G418 into 60-DOG. GenQ also showed activity with X2 as
the substrate (Figure 5A), producing a compound with theors
Figure 5. LC-MS Analysis of GenQ/GenB1-Catalyzed Dehydrogenation and Transamination of Gentamicin X2
Selective ion monitoring was carried out on (A) [M+H]+ (m/z 483) and [M+Na]+ (m/z 505) ions of gentamicin X2; (B) [M+H]+ (m/z 481) and [M+Na]+ (m/z 503) ions of
60-DOX, the product of GenQ-catalyzed 60-dehydrogenation of gentamicin X2; (C) [M+H]+ (m/z 482) and [M+Na]+ (m/z 504) ions of JI-20A, the product of GenB1-
catalyzed 60-amination of 60-DOX using L-methionine as an amino donor. MS/MS analysis of [M+H]+ (m/z 483), [M+H]+ (m/z 481) and [M+H]+ (m/z 482) ions are also
shown. See also Figures S6 and S7.
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Figure 5B). Tandem mass spectrometry (MS-MS) analysis of the
species with m/z 517 and m/z 481 gave fragmentation patterns
fully consistent with dehydrogenation having occurred in the
side chain of the 60-methyl-glucosamine ring of G418 and in
the glucosamine ring of X2, respectively.
Multiple Aminotransferases Are Capable of
C-60-Transamination of Gentamicin Biosynthetic
Intermediates In Vitro
The gene products of genB1, genB2, genB3, and genB4 were
all considered plausible candidate enzymes to partner GenQ
in 60-dehydrogenation-transamination, based on their significantChemsequence similarity to Neo18, a previously-characterized gluta-
mate: 60-dehydroparomamine aminotransferase (Huang et al.,
2007; Figure S4A). Recombinant GenB1, GenB2, GenB3, and
GenB4 were expressed in E. coli (Figure S6B). All four purified
proteins were yellow and had UV-visible absorption spectra
typical of aminotransferases containing bound pyridoxal-50-
phosphate cofactor (Figure S6D). GenB1, GenB2, GenB3, and
GenB4 were each tested for their ability to catalyze the transam-
ination of the aldehyde 60-DOX to form JI-20A; and to catalyze
transamination of the ketone 60-DOG to form JI-20B. In these
coupled assays, carried out as detailed in Experimental Proce-
dures, L-ornithine, N-acetyl-L-ornithine, D-arginine, S-adenosyl-
L-methionine, and all proteinogenic amino acids except L-prolineistry & Biology 21, 608–618, May 22, 2014 ª2014 The Authors 613
Figure 6. Coupled In Vitro Analysis of
Aminotransferase Activities of Individual
GenB Enzymes
(A) Amination of 60-DOG generated in situ from
G418 by the reaction of GenQ.
(B) Amination of 60-DOX generated in situ from
gentamicin X2 by the reaction of GenQ; Reaction
mixtures were analyzed after incubation for 16 hr.
The amino donor was L-methionine.
See also Figures S6 and S7.
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were analyzed with LC-ESI-MS (Figures 4, 5, and S7).
GenQandGenB1 together catalyzed the conversion ofG418 to
JI-20B,with L-methionine as themost effective aminodonor (80%
conversion) (Figure 4 and S7Ai). Other amino donors tested
except L-threonine and L were also accepted as substrates by
GenB1, but the yield of JI-20B never exceeded 37% conversion.
WhenGenB2was used instead of GenB1, low level of conversion
to JI-20B was observed when either L-Lys (7%), L-Met (9%) or
L-Tyr (16%) was used as amino donor (Figure S7Aii). GenB3
also showed some activity (17% conversion), but only with L-Gln
as the amino donor (Figure S7Aiii). GenB4, in contrast, did not
show activity with any of the amino donors tested (Figure S7Aiv).
The combination of GenB1 and GenQ also catalyzed the con-
version of gentamicin X2 into JI-20A, with L-Met and L-Orn as
the only effective amino donors (54% and 70% conversion,
respectively; Figure 5andS7Av).GenB2showedmarginal activity
(<5% conversion) on 60-DOX, and only when L-Gln, L-Lys, L-Met,
or L-Phe were used as the amino donors (Figure S7Avi). GenB3
accepted all amino donors tested with L-Orn giving 50% con-
version; Figure S7Avii). Gentamicin X2 was a very poor substrate
(<6% conversion) for the combination of GenQ and GenB4 (Fig-
ure S7Aviii). When the aminotransferase activities of GenB1,
GenB2, GenB 3, and GenB4 on 60-DOG and 60-DOX in the pres-
ence of L-methionine were compared, GenB1 clearly showed
the highest activity, on both substrates (Figure 6). Although it
cannot be ruled out that another amino acid donor is preferred
in vivo, the robust activity seenwith L-methionine in vitro suggests
that this is likely to be the physiological substrate.
GenB2 Catalyzes In Vitro Epimerization of Gentamicin
C2 and Gentamicin C2a
Given the evidence that the chief role of GenB2, GenB3, and
GenB4 is in the unexplored dehydroxylation stage of gentamicin614 Chemistry & Biology 21, 608–618, May 22, 2014 ª2014 The AuthorsC biosynthesis, we investigated their
possible involvement in the generation of
gentamicin C2a, which like G418 and
gentamicins C2 and C1 is methylated at
the C-60 position but which has the oppo-
site configuration at this stereocenter
(Figure 1). Purified recombinant GenB en-
zymes were assayed for their ability to
catalyze the epimerization of gentamicin
C2 into C2a, as described in the Experi-
mental Procedures. GenB1, GenB3, and
GenB4 showed no activity, as judged by
LC-ESI-MS analysis of reaction mixtures.In contrast, GenB2 did catalyze the epimerization of C2, to form a
mixture of C2 and C2a in a molar ratio of 1:2 (Figure S7B).
Furthermore, when C2a was used as the substrate the reverse
reaction was also detected and the final product mixture was
found to contain the C2 and C2a epimers in the samemolar ratio
of 1:2 (Figure S7B), implying that equilibrium had been reached.
DISCUSSION
The results presented here significantly advance our understand-
ing of the biosynthetic pathway to the gentamicin C complex, an
established drug used to combat life-threatening infections. The
task of assigning functions to individual gene products involved
in the pathway is not trivial because the cluster contains
multiple,mutually homologous genes formethyltransferases, ox-
idoreductases, and aminotransferases with potential for overlap-
ping substrate specificities. Therearenumerousprecedents from
other aminoglycoside pathways for enzyme promiscuity or even
dual function (Huang et al., 2005, 2007; Fan et al., 2008;
Yokoyama et al., 2008; Park et al., 2011). From our analysis of
theDgenQDgenKmutant it is clear that GenK andGenQ uniquely
control the fate of gentamicin X2 at the biosynthetic branch point.
No other enzymes inM. echinosporawere able to take over these
roles under the fermentation conditions used. This is in contrast
to (for example) the neomycin biosynthetic pathway, where the
GenQ homolog Neo11 is proposed to function both as a 60-
paromamine dehydrogenase and then later in the pathway as
the C-60 0 0-dehydrogenase acting on ring IV of neomycin (Llewel-
lyn and Spencer, 2006; Huang et al., 2007; Kudo et al., 2009;
Clausnitzer et al., 2011).
We have confirmed the important findings from several labora-
tories (Karki et al., 2012; Hong and Yan, 2012; Li et al., 2013)
that the flux in the DgenK mutant is diverted exclusively
down the ‘‘left-hand’’ branch (Figure 1) to C-60-unmethylated
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we have shown that chemical complementation of this mutant
with G418 fully restores the flux down the ‘‘right-hand’’ branch
(Figure 1) to wild-type levels. In contrast to the results with the
DgenK mutant, the DgenQ mutant was unexpectedly found to
be blocked in both branches of the pathway, accumulating
both X2 and G418. This observation rules out any other dehydro-
genase from the gentamicin cluster (such as GenD2 or GenD3)
being capable of specific C-60-dehydrogenation of G418. This
observation also showed that it would not be possible by dele-
tion of genQ to enhance selective production of those genta-
micin C complex components synthesized via the ‘‘right-hand’’
branch.
We next turned our attention to the potential roles of the four
genes predicted to encodeClass III pyridoxal phosphate-depen-
dent aminotransferases: genB1, genB2, genB3, and genB4. We
anticipated that there might be considerable substrate overlap
and promiscuity shown by these enzymes, and we therefore
constructed and analyzed the complete combinatorial set of 15
mutants in which one, two, three, or all four of these genes had
been independently deleted in-frame. LC-ESI-HRMS analysis
of these mutant strains revealed several important insights into
the enzymology of gentamicin biosynthesis.
First, the quadruple mutant DgenB4DgenB1DgenB3DgenB2
was unable to produce any intermediate more advanced than
X2 and G418, which implies that one or more of these genes en-
codes an aminotransferase that partners GenQ. Analysis of the
triple mutants in which only one of these four was active revealed
a major role for GenB1 in partnering the GenQ dehydrogenase in
the amination of both X2 and G418, but also revealed a low-level
promiscuity of the other GenB enzymes that allows thempartially
to replace GenB1 in the amination steps.
The analysis of mutants lacking either genB3 or genB4
showed that biosynthesis of all members of the gentamicin C
complex was blocked, with accumulation of the known interme-
diates JI-20A and JI-20B. GenB3 and GenB4 appear therefore
to participate, perhaps as pyridoxal-dependent dehydratases,
in the multistep removal of the two unactivated hydroxyl groups
from one of the sugar rings. Deletion of genB2markedly lowered
production of gentamicins C1a and C2b in the ‘‘left-hand’’
branch, perhaps through build-up of inhibitory metabolites;
and blocked the production of C2 and C1, two of the three com-
ponents of the gentamicin C complex that are produced in the
‘‘right-hand’’ branch of the pathway. The level of C2a in contrast
rose over 7-fold, clearly implicating this stereoisomer as the first-
formed product of didehydroxylation of JI-20B and identifying
GenB2 as the catalyst for its epimerization to C2 (Figure 1).
We expressed and affinity-purified GenQ from recombinant
E. coli as a soluble protein containing FAD. By using G418 as
substrate for this enzyme, we have obtained LC-ESI-MS and
MS-MS evidence for the production of the putative ketone inter-
mediate 60-DOG. Analogously, when GenQ was incubated with
X2 as substrate the observed MS-MS fragmentation spectrum
of the product was consistent with that expected for the pre-
dicted aldehyde intermediate 60-DOX. We also expressed and
purified GenB1, GenB2, GenB3, and GenB4 from recombinant
E. coli as soluble enzymes containing pyridoxal phosphate,
and this allowed us to reconstitute amination from X2 to JI-20A
and from G418 to JI-20B respectively, by coupling the GenQ-Chemcatalyzed reaction to subsequent transamination catalyzed by
one of these four enzymes. GenB1 proved far superior to the
other three GenB enzymes in catalyzing these in vitro conver-
sions, with L-methionine consistently the best amino donor
among the many amino acids screened. These results are in
good agreement with the data from our fermentation of GenB-
deficient mutants (Table S1). From these results we conclude
that GenB1 is the major, though not the exclusive, partner for
GenQ in the dehydrogenation-transamination of both X2 and
G418.
GenB3 and GenB4 are likely to cooperate with other enzymes
in the 30,40-didehydroxylation of both JI-20A and JI-20B. Recent
in vitro evidence using a substrate analog (Shao et al., 2013) im-
plicates the phosphotransferase GenP in initiating this process,
through phosphorylation at the C-30 hydroxy group. Sisomicin,
an antibiotic naturally produced by M. inyoensis (Reimann
et al., 1974), is a 40,50-dehydro-derivative of gentamicin C1a. It
has also been described as a minor component of the genta-
micin fermentation of M. echinospora (Be´rdy et al., 1977).
When added to resting cells of mutant M. echinospora,
M. sagamiensis (Kase et al., 1982b), or M. rhodorangea (Lee
et al., 1977) blocked early in the gentamicin pathway, sisomicin
is reportedly converted into gentamicin C1a and C2b. Analo-
gously, verdamicin C2a (40,50-dehydro-gentamicin C2a) is an
antibiotic naturally produced by M. grisea (Weinstein et al.,
1975), which reportedly can be bioconverted by an early stage
blocked mutant ofM. sagamiensis (Kase et al., 1982b) into gen-
tamicins C2a, C2, and C1. It remains to be determined how
closely sisomicin and verdamicin are related to genuine interme-
diates in the normal 30,40-didehydroxylation pathway that leads
to gentamicins.
A further open question has been the origin of gentamicin C2a,
theminor C-60 epimer of C2. A blockedmutant ofM. sagamiensis
(KY 11564) has been described (Kase et al., 1982a), which accu-
mulates gentamicin C2a but neither C2 nor C1. Another mutant
that appears to be blocked earlier in the pathway bioconverts
verdamicin C2a into gentamicin C2a then into C2 and C1 (Kase
et al., 1982b). From the results obtained here from fermentation
of the DgenB2 mutant, it is clear that this gene is required for
formation of C2 but not for C2a. We investigated a possible role
for GenB1, GenB2, GenB3, or GenB4 in interconverting gentami-
cinsC2 andC2a.Remarkably, purifiedGenB2 (but not the others)
proved competent in vitro to catalyze the 60-epimerization of
gentamicin C2a into gentamicin C2 (and vice versa). This
evidence strongly supports the original proposal (Kase et al.,
1982b) that C2a is an obligatory precursor to C2, which in turn
implies that two inversions of the configuration at the C-60 posi-
tion occur during the transformation of G418 into gentamicin C2.
SIGNIFICANCE
Aminoglycosides, mainly produced by actinobacteria,
constitute a widespread and versatile group of bioactive
natural products. Examples of clinically used aminoglyco-
sides include gentamicin to treat neonatal sepsis; kana-
mycin and amikacin to treat MRSA; and paromomycin to
treat visceral leishmaniasis. Aminoglycosides are also under
active investigation for their anti-HIV properties and in
attempts to rescue certain genetic conditions by allowingistry & Biology 21, 608–618, May 22, 2014 ª2014 The Authors 615
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particular is of continuing interest despite its known toxicity
because of its remarkable potency in combating systemic
Gram-negative infections. The perspective of a safer and
less expensive gentamicin through administration of a sin-
gle component, or using a single component for semisyn-
thesis of a novel derivative, is therefore very attractive. The
work we report here has used complementary in vivo and
in vitro approaches to identify the key enzymes that control
the branch point in the gentamicin biosynthetic pathway. It
has also revealed the involvement of the pyridoxal phos-
phate-dependent enzymes GenB2, GenB3, and GenB4 in
the subsequent steps. By more closely defining the molecu-
lar enzymology of the pathway in Micromonospora echino-
spora, this work has brought closer the goal of assembling
a defined set of pathway enzymes thatmight in future deliver
single gentamicin C components in a scaleable and sustain-
able synthetic biology process.
EXPERIMENTAL PROCEDURES
Bacterial Strains, Chemicals, and Culture Conditions
E. coli DH10B and NovaBlue strains were used as cloning hosts, and E. coli
BL21(DE3) for protein expression. E. coli ET12567/pUZ8002 was used for
intergeneric conjugation between E. coli and Streptomyces (MacNeil et al.,
1992). Streptomyces fradiae NCIMB 8233 (Waksman and Lechevalier, 1949)
was the source of template DNA for cloning the neo11 gene. M. echinospora
ATCC15835 (Weinstein et al., 1963) was used for creation of in-frame deletion
mutants and as the source of gen genes. Restriction endonucleases, Phusion
High-Fidelity Master Mix with GC-buffer, and T4 DNA ligase were from NEB
England Biolabs. Pfu DNA polymerase was from Fermentas. Oligonucleotide
primers were synthesized by either GenScript or Invitrogen. DNA sequencing
of PCR products was performed by GenScript or by the Department of
Biochemistry DNA Sequencing Facility, University of Cambridge. DIG DNA
labeling and detection kits were from Roche. G418 used for feeding studies
was obtained from GIBCO. For in vitro enzyme assays, G418 and amino acids
were from Sigma-Aldrich, gentamicin X2 was from Toku-E, and S-adenosyl
methionine was from Carbosynth.
M. echinospora ATCC15835 wild-type and mutants were grown in ATCC
Medium 172 (glucose 10 g, soluble starch 20 g, yeast extract 5 g, N-Z amine
type A 5 g, CaCO3 1 g, 1 l distilled water) for chromosomal DNA isolation
and preparation of mycelium. E. coli strains were maintained in 2 3 TY or LB
media at 37C with the appropriate antibiotic selection at a final concentration
of 25 mg/ml apramycin, 100 mg/ml, carbenicillin, 25 mg/ml chloramphenicol,
25 mg/ml or 50 mg/ml kanamycin, 15 mg/ml tetracycline, or 25 mg/ml
thiostrepton.
For production of gentamicin C complex and intermediates,M. echinospora
ATCC15835 and its mutants were cultured in two stages. A seed culture was
maintained in liquid ATCC 172 medium at 28C with shaking at 220 rpm
for 2 days before being inoculated into fresh liquid ATCC 172 Medium. The
production fermentation was incubated at 28C with shaking for 8 days. For
feeding experiments, filter-sterilized compounds (50 mg/ml) were added to
the medium just before addition of the seed culture.
Construction of Gene Disruption Plasmids
For in-frame deletion, DNA fragments flanking each target genewere amplified
from the genomic DNA of M. echinospora ATCC15835 (see List of Primers
Used in the Supplemental Information). The PCR products were each cloned
into pUC18, then cut out and cloned together into the Streptomyces-E. coli
shuttle vector pYH7 (Sun et al., 2009) to obtain the following gene disruption
plasmids: pYH286 (for DgenQ), pWHU1 (for DgenK), pWHU4 (for DgenB1),
pWHU2 (for DgenB2), pWHU5 (for DgenB3), and pWHU3 (for DgenB4; Table
S2). For generation of the DgenB4DgenB3 double mutant, DNA fragments
flanking the genB3 gene in the genB4mutant were amplified using primer pairs
gen4-genB3-L1/L2 and genB4-genB3-R1/R2 (see List of Primers Used in the616 Chemistry & Biology 21, 608–618, May 22, 2014 ª2014 The AuthSupplemental Information) and inserted into vector pYH7 to yield plasmid
pWHU43 (Tables S2 and S3). All plasmids were verified by sequencing.
Targeted In-Frame Gene Deletion
To create individual in-frame deletion mutants of genQ, genK, genB1, genB2,
genB3 and genB4, the corresponding plasmid pYH286, pWHU1, pWHU4,
pWHU2, pWHU5, and pWHU3 was introduced into the wild-type strain by
conjugation from E. coli ET12567/pUZ8002 (MacNeil et al., 1992). Apramy-
cin-sensitive (AprS) colonies were counterselected from the initial AprR excon-
jugants after nonselective growth. The AprS exconjugants were confirmed by
PCR amplification with appropriate checking primers and by Southern hybrid-
ization (Figures S2 and S4B). DgenQDgenK was obtained by disruption of the
genK gene in the DgenQ mutant using plasmid pWHU1 (Figure S2 and Tables
S2 and S3). Similarly, the double-, triple-, and quadruple-in-frame deletion
mutants of genB genes in all combinations were created by disruption of target
gene(s) in appropriate mutants (Figure S4B and Table S3).
Complementation of the DgenQ and DgenK Mutants
Complementation plasmids were prepared by cloning genQ, genK and neo11,
respectively, into pWHU77 (a plasmid derived from pIB139 (Wilkinson et al.,
2002; Del Vecchio et al., 2003) with the apramycin resistance gene replaced
by a thiostrepton resistance gene) under the control of the PermE* promoter
(Figure S2(4)D). The genQ and genK were amplified from the genomic DNA
of M. echinospora ATCC15835 using primer pairs genQ-EP1/genQ-EP2 and
genK-EP1/genK-EP2 (see List of Primers Used in the Supplemental Informa-
tion), respectively. Primers neo11-EP1 and neo11-EP2 were used to amplify
neo11 from S. fradiae NCIMB8233. The PCR products were inserted into
pWHU77 between the NdeI and EcoRI sites to give pWHU163 (genQ),
pWHU165 (neo11), and pWHU67 (genK; Table S2). After sequence confirma-
tion, these plasmids were introduced individually into DgenQ (pWHU163 and
pWHU165) and DgenK (pWHU67) by conjugation. Complemented exconju-
gants were verified based on thiostrepton resistance and confirmed by PCR
(Figures S2(4)A to S2(4)C).
Extraction and LC-ESI-HRMSAnalysis of Gentamicin CComplex and
Intermediates
Cultures of wild-type and mutant strains of M. echinospora ATCC15835 were
adjusted to pH 2.0 with HCl and the acidified broth was agitated overnight on a
laboratory rocker. The clarified supernatant after centrifugation was filtered
through Whatman filter paper, applied to a column of DOWEX 50 WX8-200
ion-exchange resin (2 g), preconditioned with 50 ml acetonitrile followed by
50 ml MilliQ water, and equilibrated with 50 ml of 10 mM HCl. The column
was washed with 30 ml of 10 mM HCl and eluted with 10 ml of 1 M NH4OH.
The eluate was freeze-dried, redissolved in 1 ml MilliQ water, and filtered
through 0.22 mm microporous membrane before subjection to LC-ESI-
HRMS analysis.
Cloning of genQ, genB1, genB2, genB3, and genB4 Genes for
Expression in E. coli
Genes genQ, genB1, genB2, genB3, and genB4 were amplified from the
genomic DNA of M. echinospora ATCC15835 by PCR (see List of Primers
Used in Supplemental Information). PCR was carried out using Pfu DNA poly-
merase with 25 cycles of denaturation at 94C for 1 min, annealing at 60C for
1 min, and extension at 72C for 2 min plus final extension at 72C for 10 min.
The PCR products were digested with appropriate restriction enzymes, puri-
fied by gel extraction (Fermentas), and inserted into plasmid pET28a(+). The
resulting constructs (Table S2) were verified by DNA sequencing.
Overexpression and Purification of Recombinant Proteins
E. coli BL21(DE3) cells containing the recombinant plasmids were cultured in
LB broth containing kanamycin (50 mg/ml) at 37C to absorption at 600 nm of
0.5 to 0.8 and expression induced by isopropylthiogalactoside (0.1 mM) at
16Cwith shaking overnight. Cells were harvested and resuspended in binding
buffer (0.5 M NaCl, 20 mM Tris-HCl [pH 7.9]). The recombinant protein was
released by sonication for 4 min using a 2 s on/6 s off cycle. Clarified cell lysate
was passed through a column of Co2+-charged His-Bind resin (GE Health-
care). After washing the column with washing buffer (0.5 M NaCl, 5-60 mM
imidazole, 20 mM Tris-HCl [pH 7.9]). N-His6-tagged recombinant proteinsors
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[pH 7.9]). Imidazole in the eluted protein solutions was removed by buffer ex-
change using Amicon Ultracentrifugal filters (Millipore). The purified proteins
were stored at20C in 250mMNaCl, 10mMTris-HCl, pH 7.9, and 50%glyc-
erol. The identities of the purified proteins were confirmed by SDS-PAGE,
UV-Vis absorbance analysis and LC-ESI-MS (Thermo Finnigan). Protein con-
centrations were determined using Bradford protein dye reagent (Sigma).
Enzyme Assays
Assay mixtures for GenQ (50 ml) contained substrate (200 mM) and purified
GenQ (16 mM) in Tris-HCl buffer (50 mM, pH 8.0). Coupled assays with
GenQ and GenB (B = B1, B2, B3, or B4) contained substrate (200 mM), amino
donor (2mM), GenQ (16 mM), andGenB (20 mM) in 50 ml Tris-HCl buffer (50mM,
pH 8.0). The isomerase activity assays contained substrate (C2 or C2a,
200 mM) and each one of the four GenB enzymes (20 mM), respectively, in
50 ml Tris-HCl buffer (50 mM, pH 8.0). These high concentrations of each
enzyme were chosen based on previous work with the GenQ homolog
Neo11 (Huang et al., 2007) where the enzyme was found to be unstable during
incubations. Incubations were at 30C overnight and quenched by addition of
chloroform (100 ml) followed by vortexing and centrifugation to remove protein.
The supernatants were analyzed by LC-ESI-MS.
LC-ESI-MS Analyses
LC-ESI-HRMS analysis of extracts of wild-type and mutant strains of
M. echinospora ATCC15835 was performed on a Thermo Electron LTQ-Orbi-
trap XL fitted with a Phenomenex Luna C18 column at a flow rate of 0.4 ml/min
using a mobile phase of (A) 0.2% trifluoroacetic acid (TFA) in H2O (adjusted to
pH 2.0 with NH4OH) and (B) 100% CH3CN; the gradient for separation of both
gentamicin C complex and related intermediates: 0–18 min 2% B to 14% B,
18–19 min 14% B to 40% B, 19–24 min 40% B, 24–25 min 40% B to 2% B,
25–30 min 2% B. The gradient for separation of gentamicin C complex: 0–
14 min 2% B to 6% B, 14–16 min 6% B to 8% B, 16–25 min 8% B-15% B,
25–26 min 15% B to 40% B, 26–34 min 40% B, 34–35 min 40% B to 2% B,
35–45 min 2%B. LC-ESI-MS analysis of assay mixtures and proteins was car-
ried out on a Thermo Finnigan LCQ connected to an Agilent HP 1100 HPLC
system. Deproteinated assay mixtures were separated on a Prodigy C18 col-
umn (Phenomenex) at a 0.4 ml/min flow rate using a mobile phase of (A) 0.3%
TFA in H2O and (B) 0.1% TFA in CH3CN; 98% A for 10 min, gradient to 90% B
over 15 min, then 90%B for 5 min followed by a gradient from 90%B to 2% B.
MS/MS analyses were carried out in the positive ionization mode with 35%
relative collision energy. Aminoglycosides were quantified by integration of
areas under peaks. For proteins, a Nucleosil C4 column (250 3 2 mm, 5 mm,
Macherery-Nagel) was used at a flow rate of 0.2 ml/min with the following con-
ditions: mobile phase (A) H2O 0.1% TFA and (B) CH3CN 0.1% TFA; 35% B to
45% B over 5 min, increase the gradient of B to 75% over 20 min, 95% B for
2min, 95%B for 7min, followed by a gradient from 95%B to 35%Bover 3min.
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